Humana Inc (HUM · NYSE)
HUM · MARKET VIEW
Market view · as of Sep 21, 2026
Price (last ~year)
Humana's latest quarter (June 30, 2026) showed revenue of $40.87B, up from $39.65B the prior quarter, with net income of $693.0M, though operating income of $1.36B and EBITDA of $1.31B both declined sequentially from March. The company has beaten estimates in all four of its last earnings reports, including a 22.3% beat in the most recent quarter ($7.61 reported vs. $6.22 estimated), and revenue grew 26.2% year over year to $145.68B TTM. Cash flow remains a weak point, with operating cash flow of -$426.0M and free cash flow of -$558.0M in the June quarter, alongside total debt of $14.25B at 4.0x EBITDA. The stock closed at $386.22, up 7.0% over three months and 35.0% above its 200-day SMA, trading near its 52-week high (-5.8%), with Wall Street Zen upgrading shares to Buy and Nykredit making a new $12.46M investment.
Valuation
- Market cap
- $46.38B
- P/E
- 36.5
- PEG
- 1.293
- P/B
- 2.414
- P/S
- 0.318
- Beta
- 0.745
- Analyst target
- $419.04
Quality & returns
- Gross margin
- 13.7%
- Operating margin
- 3.5%
- Profit margin
- 0.9%
- ROE
- 6.9%
- ROA
- 3.9%
Price movement
- Last
- $386.22
- 1-month
- +1.4%
- 3-month
- +7.0%
- RSI (14)
- 50
- vs SMA200
- +35.0%
- 52-wk position
- 90.5% -5.8% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $40.87B | $1.36B | $693.0M | $1.31B |
| 2026-03-31 | $39.65B | $1.58B | $1.19B | $1.97B |
| 2025-12-31 | $32.52B | $-1.02B | $-796.0M | $-685.0M |
| 2025-09-30 | $32.65B | $108.0M | $195.0M | $480.0M |
Recent news
- Somewhat-Bullish Nykredit A S Makes New $12.46 Million Investment in Humana Inc. $HUM · 2026-09-21
- Somewhat-Bullish Humana (NYSE:HUM) Upgraded to "Buy" at Wall Street Zen · 2026-09-19
- Neutral HCA Healthcare Sees Solid Demand as Exchange Headwinds Pressure 2026 Outlook · 2026-09-18
- Neutral NewJersey Resources (NJR) Stock Price, News & Analysis $NJR · 2026-09-17
- Somewhat-Bullish Can Centene Sustain Its Turnaround Amid Membership Pressure? · 2026-09-17
- Somewhat-Bullish CVS Health's Aetna to streamline cancer treatment approvals · 2026-09-17
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)